{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:34:27Z","timestamp":1777512867701,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Vemurafenib, an oral agent that selectively targets the BRAF V600E mutation, has recently emerged as the mainstay of treatment in patients with BRAF-positive stage IV melanoma. A spectrum of cutaneous adverse events has been associated with vemurafenib, ranging from benign rashes to malignant side effects such as keratoacanthoma and squamous cell carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>In this article, we review clinical data regarding the frequency and severity of the common dermatologic side effects associated with vemurafenib; case series and noncontrolled studies evaluating the safety of vemurafenib therapy are used to further characterize these adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Benign vemurafenib-induced side effects generally tend not to be severe or life threatening, with most patients managed by dose interruptions, dose reductions, or topical therapies. Squamous cell carcinomas and keratoacanthomas associated with vemurafenib therapy are easily treated by simple excision of the lesion without discontinuation of vemurafenib. Thus, awareness of potential adverse events coupled with routine dermatologic assessment and timely management will allow for optimal therapeutic benefit in patients receiving vemurafenib therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2310\/7750.2013.13120","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T15:01:24Z","timestamp":1426086084000},"page":"223-228","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Cutaneous Adverse Events during Vemurafenib Therapy"],"prefix":"10.1177","volume":"18","author":[{"given":"Shivani Felicia","family":"Chandrakumar","sequence":"first","affiliation":[{"name":"From the Department of Dermatology and Skin Care at Women's College Hospital and Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and Skin Care at Women's College Hospital and Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,7,1]]},"reference":[{"key":"bibr1-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21166"},{"key":"bibr2-7750.2013.13120","first-page":"193","volume":"181","author":"Barth A","year":"1995","journal-title":"J Am Coll Surg"},{"key":"bibr3-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0253"},{"key":"bibr4-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.1.158"},{"key":"bibr5-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67482-X"},{"key":"bibr6-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.3799"},{"key":"bibr7-7750.2013.13120","first-page":"1947","volume":"24","author":"Gogas H","year":"2004","journal-title":"Anticancer Res"},{"key":"bibr8-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2007.06.004"},{"key":"bibr9-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2012.01.008"},{"key":"bibr10-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1038\/nature00766"},{"key":"bibr11-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1016\/j.yadr.2007.07.009"},{"key":"bibr12-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.737780"},{"key":"bibr13-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002011"},{"key":"bibr14-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112302"},{"key":"bibr15-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"bibr16-7750.2013.13120","volume":"30","author":"Chapman PB","year":"2012","journal-title":"J Clin Oncol"},{"key":"bibr17-7750.2013.13120","doi-asserted-by":"crossref","unstructured":"Ribas A, Kim KB, Schuchter R, BRIM- 2: an open- label, multicenter phase II study of vemurafenib in previously treated patients with BRAFV600E mutation-positive metastatic melanoma [abstract]. J Clin Oncol 2011;Suppl.","DOI":"10.1200\/jco.2011.29.15_suppl.8509"},{"key":"bibr18-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105358"},{"key":"bibr19-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.2895"},{"key":"bibr20-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.04.008"},{"key":"bibr21-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70413-8"},{"key":"bibr22-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2012.01031.x"},{"key":"bibr23-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12010"},{"key":"bibr24-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.125"},{"key":"bibr25-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.06.045"},{"key":"bibr26-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.09.015"},{"key":"bibr27-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1371\/annotation\/d884b668-04f7-4ae6-96a3-a199df5b43be"},{"key":"bibr28-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1113752"},{"key":"bibr29-7750.2013.13120","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0049-8"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2310\/7750.2013.13120","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.2310\/7750.2013.13120","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2310\/7750.2013.13120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:46:11Z","timestamp":1777391171000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.2310\/7750.2013.13120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.2310\/7750.2013.13120"],"URL":"https:\/\/doi.org\/10.2310\/7750.2013.13120","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}